{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:45:37Z","timestamp":1782456337161,"version":"3.54.5"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:p>Valganciclovir is widely used as prophylaxis against cytomegalovirus (CMV) infection following solid organ transplantation. However, valganciclovir requires dose adjustment based on kidney function. This retrospective observational study at a London kidney transplant center explored the accuracy of valganciclovir dosing in the first 3 months following transplantation and its impact on clinical outcomes. Data for adult kidney transplant recipients (KTRs) receiving valgancivloir prophylaxis between 2017 to 2019 was analyzed. The primary outcome was the difference between the prescribed and optimum valganciclovir dose (calculated by creatinine clearance) on days 10\u201392 after surgery. Secondary outcomes included associations between valganciclovir dosing with CMV DNAemia, cytopenias and rejection. For the 90 KTRs included, the valganciclovir dose was optimum for 51%, underdosed for 31% and overdosed for 18% of the study period. Significant associations were shown for underdosing and CMV DNAemia (B\u00a0=\u00a02.88, SE\u00a0=\u00a01.14, p=0.01, 95% CI [1.90,166.1]) as well as overdosing and neutropenia (B\u00a0=\u00a02.29, SE 0.99, p=0.02, 95% CI [1.42,68.71]). This study highlights the difficulty in optimally dosing valganciclovir in KTRs post-operatively and importantly shows significant associations between suboptimal dosing and clinical outcomes.<\/jats:p>","DOI":"10.3389\/fneph.2026.1781576","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:45:33Z","timestamp":1782452733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Accuracy of valganciclovir dosing following kidney transplantation and its impact on clinical outcomes"],"prefix":"10.3389","volume":"6","author":[{"given":"Jessica","family":"Forsyth","sequence":"first","affiliation":[{"name":"Department of Renal Medicine & Transplantation, Royal London Hospital, Barts Health National Health Service Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Randall","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine & Transplantation, Royal London Hospital, Barts Health National Health Service Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Thuraisingham","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine & Transplantation, Royal London Hospital, Barts Health National Health Service Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200531152901","article-title":"Cytomegalovirus in solid organ transplant recipients: Clinical updates, challenges and future directions","volume":"26","author":"Razonable","year":"2020","journal-title":"Curr Pharm Des"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/JAMBIO\/LXAE292","article-title":"Epidemiology and pathogen characteristics of infections following solid organ transplantation","volume":"135","author":"Meng","year":"2024","journal-title":"J Appl Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000230460.42558.b0","article-title":"The natural course of cytomegalovirus infection and disease in renal transplant recipients","volume":"82","author":"Hartmann","year":"2006","journal-title":"Transplantation"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01190.x","article-title":"The impact of early cytomegalovirus infection and disease in renal transplant recipients","volume":"11","author":"Sagedal","year":"2005","journal-title":"Clin Microbiol Infection"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/CTR.13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/TID.14227","article-title":"Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease","volume":"26","author":"Belga","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003774.PUB5","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","volume":"5","author":"Vernooij","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","article-title":"Valganciclovir","year":"2026","journal-title":"Br Natl Formulary"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.12712","article-title":"Pitfalls in valganciclovir prophylaxis dose adjustment based on renal function in kidney transplant recipients","volume":"37","author":"Hammer","year":"2024","journal-title":"Transplant Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/15269248211046037","article-title":"Low-dose valganciclovir prophylaxis is safe and cost-saving in CMV-seropositive kidney transplant recipients","volume":"31","author":"Shi","year":"2021","journal-title":"Prog Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000570","article-title":"Evaluation of low- versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients","volume":"99","author":"Gabardi","year":"2015","journal-title":"Transplantation"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12609","article-title":"Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+\/R+) renal transplant recipients","volume":"18","author":"Heldenbrand","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2015.0305","article-title":"Efficacy and safety of low-dose versus standard-dose valganciclovir for prevention of cytomegalovirus disease in intermediate-risk kidney transplant recipients","volume":"14","author":"Halim","year":"2016","journal-title":"Exp Clin Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/JAMA.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: A randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"B16","volume-title":"Pharmacoeconomic review report: letermovir (Prevymis) - NCBI bookshelf","year":"2018"},{"key":"B17","article-title":"NICE. Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)","year":"2025"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/TID.12849","article-title":"Impact of electronic health record-based, pharmacist-driven valganciclovir dose optimization in solid organ transplant recipients","volume":"20","author":"Hensler","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/TID.13864","article-title":"Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard","volume":"24","author":"Jorgenson","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/ajt.16743","article-title":"White paper on antimicrobial stewardship in solid organ transplant recipients","volume":"22","author":"So","year":"2022","journal-title":"Am J Transplant"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1781576\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:45:33Z","timestamp":1782452733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1781576\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":20,"alternative-id":["10.3389\/fneph.2026.1781576"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1781576","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1781576"}}